These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20857706)

  • 1. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide for type 2 diabetes?
    Drug Ther Bull; 2010 May; 48(5):50-3. PubMed ID: 20447980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
    Gross B
    J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].
    Scheen AJ
    Rev Med Liege; 2015 Apr; 70(4):207-14. PubMed ID: 26054173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].
    Scheen AJ; Radermecker RP; Philips JC; Paquot N
    Rev Med Suisse; 2007 Aug; 3(122):1884, 1886-8. PubMed ID: 17896662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Liraglutide].
    Takahashi T; Odawara M
    Nihon Rinsho; 2011 May; 69(5):883-9. PubMed ID: 21595276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide in type 2 diabetes mellitus.
    Baruah MP; Chaudhury T; Sethi BK; Dharmalingam M
    J Indian Med Assoc; 2012 May; 110(5):335-8. PubMed ID: 23360033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.